drugset / Trial / NCT04089904
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
Timeline
- Start
- 2019-10-11
- Primary completion
- 2023-03-11
- Completion
- 2023-03-11
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |